[go: up one dir, main page]

PA8801901A1 - Suspension pediatrica estabilizada de carisbamato - Google Patents

Suspension pediatrica estabilizada de carisbamato

Info

Publication number
PA8801901A1
PA8801901A1 PA20088801901A PA8801901A PA8801901A1 PA 8801901 A1 PA8801901 A1 PA 8801901A1 PA 20088801901 A PA20088801901 A PA 20088801901A PA 8801901 A PA8801901 A PA 8801901A PA 8801901 A1 PA8801901 A1 PA 8801901A1
Authority
PA
Panama
Prior art keywords
stabilized
carisbamato
suspension
pediatric
pediatric suspension
Prior art date
Application number
PA20088801901A
Other languages
English (en)
Inventor
Embrechts Roger
De Leersnijder Cedric
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40386492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8801901(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8801901A1 publication Critical patent/PA8801901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN PROVEE UNA SUSPENSIÓN FARMACÉUTICA ESTABILIZADA DE CARISBAMATO PARA USO PEDIÁTRICO Y EN ADULTOS. MÁS EN PARTICULAR,LA SUSPENSIÓN SE ESTABILIZA CON HIPROMELOSA(HPMC)PARA EVITAR EL CRECIMIENTO DE CRISTALES DE LAS PARTICULAS SUSPENDIDAS Y PARA EVITAR LA RECRISTALIZACIÓN DEL PRODUCTO FARMACOLÓGICO CON CAMBIO A LA FORMA POLIMÓRFICA.
PA20088801901A 2007-10-31 2008-10-29 Suspension pediatrica estabilizada de carisbamato PA8801901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98414407P 2007-10-31 2007-10-31

Publications (1)

Publication Number Publication Date
PA8801901A1 true PA8801901A1 (es) 2009-06-23

Family

ID=40386492

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088801901A PA8801901A1 (es) 2007-10-31 2008-10-29 Suspension pediatrica estabilizada de carisbamato

Country Status (26)

Country Link
US (4) US8263652B2 (es)
EP (1) EP2214637B1 (es)
JP (3) JP5841333B2 (es)
KR (1) KR101568681B1 (es)
CN (2) CN104840971A (es)
AR (1) AR069125A1 (es)
AU (1) AU2008320458B2 (es)
BR (1) BRPI0818118B8 (es)
CA (1) CA2703971C (es)
CL (1) CL2008003261A1 (es)
CO (1) CO6270300A2 (es)
CR (1) CR11550A (es)
EA (1) EA019881B1 (es)
EC (1) ECSP10010208A (es)
ES (1) ES2432666T3 (es)
IL (1) IL205352A (es)
MX (1) MX2010004889A (es)
MY (1) MY154063A (es)
NI (1) NI201000076A (es)
PA (1) PA8801901A1 (es)
PE (1) PE20090951A1 (es)
PL (1) PL2214637T3 (es)
TW (1) TW200934531A (es)
UY (1) UY31444A1 (es)
WO (1) WO2009056980A1 (es)
ZA (1) ZA201003848B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
WO2011107855A2 (en) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
CN102971296B (zh) 2010-04-30 2015-11-25 百时美施贵宝公司 包含n-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1，2-二氢吡啶-3-羧酰胺的药物组合物
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
TWI679977B (zh) * 2011-10-19 2019-12-21 大塚製藥股份有限公司 口服溶液
TWI660748B (zh) * 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
CN103966680A (zh) * 2014-05-04 2014-08-06 东华大学 一种药物缓释纳米纤维的制备方法
TW201717929A (zh) * 2015-05-22 2017-06-01 愛思開生物製藥股份有限公司 包括卡立胺酯之藥物及其於預防、緩解或治療疼痛或癲癎之用途
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CN105997866B (zh) * 2016-07-13 2019-08-20 成都明慈医药科技有限公司 一种含地塞米松的混悬剂及其制备方法
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
KR102369827B1 (ko) 2020-09-04 2022-03-04 (주)피알지에스앤텍 프로게리닌을 포함하는 나노현탁액 및 이의 제조방법
US20220213802A1 (en) * 2021-01-06 2022-07-07 General Electric Company System for controlling blade clearances within a gas turbine engine
KR102686558B1 (ko) 2022-01-25 2024-07-22 (주)피알지에스앤텍 프로게리닌을 포함하는 과립제 및 이를 이용한 샤셋제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265728A (en) 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
EP0785783A1 (en) * 1994-10-14 1997-07-30 Janssen Pharmaceutica N.V. Sabeluzole oral suspensions
US5698588A (en) 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US6562865B1 (en) * 1999-08-20 2003-05-13 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
BR0207830A (pt) * 2001-02-27 2004-06-22 Ortho Mcneil Pharm Inc Compostos de carbamato para uso em prevenir ou tratar distúrbios de ansiedade
KR100803796B1 (ko) * 2003-06-17 2008-02-14 화이자 인코포레이티드 세로토닌 및 노르아드레날린 재흡수 억제제로서의ｎ-피롤리딘-3-일-아미드 유도체
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
EP2089002A1 (en) * 2006-10-13 2009-08-19 Janssen Pharmaceutica, N.V. Phenylalkyl carbamate compositions
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate

Also Published As

Publication number Publication date
KR20100092944A (ko) 2010-08-23
US10201519B2 (en) 2019-02-12
JP2014193913A (ja) 2014-10-09
IL205352A0 (en) 2010-12-30
US20160008476A1 (en) 2016-01-14
US9161913B2 (en) 2015-10-20
ES2432666T3 (es) 2013-12-04
UY31444A1 (es) 2009-04-30
JP2016216486A (ja) 2016-12-22
ECSP10010208A (es) 2010-06-29
US20090111872A1 (en) 2009-04-30
EA201070534A1 (ru) 2010-12-30
EA019881B1 (ru) 2014-07-30
BRPI0818118B8 (pt) 2021-05-25
CR11550A (es) 2011-01-14
CN101848699A (zh) 2010-09-29
PE20090951A1 (es) 2009-07-13
US20120309826A1 (en) 2012-12-06
BRPI0818118A2 (pt) 2015-08-04
MX2010004889A (es) 2010-05-19
AR069125A1 (es) 2009-12-30
TW200934531A (en) 2009-08-16
CA2703971C (en) 2017-10-10
BRPI0818118B1 (pt) 2020-05-12
WO2009056980A1 (en) 2009-05-07
EP2214637A1 (en) 2010-08-11
ZA201003848B (en) 2011-08-31
US20170112798A1 (en) 2017-04-27
US8263652B2 (en) 2012-09-11
CO6270300A2 (es) 2011-04-20
PL2214637T3 (pl) 2013-10-31
CA2703971A1 (en) 2009-05-07
IL205352A (en) 2014-09-30
KR101568681B1 (ko) 2015-11-12
CN104840971A (zh) 2015-08-19
CL2008003261A1 (es) 2009-10-16
MY154063A (en) 2015-04-30
EP2214637B1 (en) 2013-05-08
JP5841333B2 (ja) 2016-01-13
NI201000076A (es) 2010-11-10
AU2008320458A1 (en) 2009-05-07
AU2008320458B2 (en) 2014-01-23
JP2011500870A (ja) 2011-01-06
JP6273589B2 (ja) 2018-02-07

Similar Documents

Publication Publication Date Title
PA8801901A1 (es) Suspension pediatrica estabilizada de carisbamato
GT201400283A (es) Formas cristalinas de un modulador del receptor androgénico
CL2015003117A1 (es) Modificaciones en la estructura cristalina
MX2019009271A (es) Portador de sustancia fisiologicamente activa.
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
SMT201600065B (it) Procedimento per la produzione di composti di 177lu altamente puri senza supporto nonché composti di 177lu senza supporto
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
IL208832A (en) 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
HUE037064T2 (hu) Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére
BR112013022625A2 (pt) quadros policristalinos, elementos policristalinos, e métodos relacionados
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
HUE037125T2 (hu) Pirrolo-[3,2-D]pirimidin-származékok vírusfertõzések és egyéb betegségek kezelésére
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
CO6361926A2 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
CO7160067A2 (es) Formulaciones de agonistas del receptor de somatostatina
MA35002B1 (fr) Forme cristalline delta du sel d'arginine du périndopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
SV2011003919A (es) Extrudidos con sustancias activas con forma de agujas
CL2008002633A1 (es) Uso de sulfato de dextrano o un derivado farmaceuticamente aceptable del mismo que sirve para preparar un medicamento que induce la produccion endogena del factor de crecimiento de hepatocito; metodo de cultivo in vitro para crecer celulas que tiene la capacidad de producir el factor de crecimiento de hepatocitos.
TH155311A (th) รูปผลึกของ (r)-7-คลอโร-n-(ควินูคลิดิน-3-อิล)เบนโซ[b]ไธโอฟีน-2-คาร์บอกซาไมด์ไฮโดรคลอไรด์โมโนไฮเดรท
TH93116B (th) เก้าอี้
IN2012DN03074A (es)